- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy
-
- Maria E. Cabanillas
- The University of Texas MD Anderson Cancer Center, Houston, TX
-
- Mark Zafereo
- The University of Texas MD Anderson Cancer Center, Houston, TX
-
- G. Brandon Gunn
- The University of Texas MD Anderson Cancer Center, Houston, TX
-
- Renata Ferrarotto
- The University of Texas MD Anderson Cancer Center, Houston, TX
Search this article
Description
<jats:p>Anaplastic thyroid carcinoma is one of the most aggressive and deadly cancers in humans and accounts for one to two cases per million persons annually. The rarity of this malignancy and the rapidity by which it grows has been a major barrier to progress in finding effective therapies. Thus, the treatment that is the current standard of care for these patients is largely palliative, and few are cured; however, novel therapies and approaches are being studied in patients with anaplastic thyroid carcinoma and are delineated herein.</jats:p>
Journal
-
- Journal of Oncology Practice
-
Journal of Oncology Practice 12 (6), 511-518, 2016-06
American Society of Clinical Oncology (ASCO)
- Tweet
Details 詳細情報について
-
- CRID
- 1360292619913703040
-
- ISSN
- 1935469X
- 15547477
-
- Data Source
-
- Crossref